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Abstract
Specialised CF care has led to a dramatic improvement in survival in CF: in the last four decades, well above what was seen in the general
population over the same period. With the implementation of newborn screening in many European countries, centres are increasingly caring for a
cohort of patients who have minimal lung disease at diagnosis and therefore have the potential to enjoy an excellent quality of life and an even
greater life expectancy than was seen previously. To allow high quality care to be delivered throughout Europe, a landmark document was
published in 2005 that sets standards of care. Our current document builds on this work, setting standards for best practice in key aspects of CF
care. The objective of our document is to give a broad overview of the standards expected for screening, diagnosis, pre-emptive treatment of lung
disease, nutrition, complications, transplant/end of life care and psychological support. For comprehensive details of clinical care of CF, references
to the most up to date European Consensus Statements, Guidelines or Position Papers are provided in Table 1. We hope that this best practice
document will be useful to clinical teams both in countries where CF care is developing and those with established CF centres.
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1. Newborn screening and access to specialist care
from early in life
Kevin W. Southern (UK)
Anne Munck (F)
Nataliya Kashirskaya (Rus)
The ECFS Neonatal Screening Working Group (Core
Committee)
There is clear evidence to support newborn screening for CF.
Early recognition provides the foundation for future management
and prevents the delay in diagnosis that has affected so many
families [1]. Protocols should be designed to reflect the culture
and CFTR genetics of each population and minimise potential
negative impacts. Please refer to the ECFS guidelines on new-
born screening and on the management of young infants with CF
diagnosed through screening [2,3].
1.1. What population characteristics validate screening
newborn infants for cystic fibrosis?
Health authorities need to balance the benefit/risk ratio of
screening newborns for CF in their population. If the incidence
S25A.R. Smyth et al. / Journal of Cystic Fibrosis 13 (2014) S23–S42
Table 1
European consensus statements, guidelines or position papers.
First author and topic Consensus (C), guideline (G) or position papers (P) Web URL
Screening
Castellani C [118] Benchmarks for cystic fibrosis carrier screening: A European consensus
document (C)
http://www.sciencedirect.com/science/article/pii/S1569199310000275
Castellani C [2] European best practice guidelines for cystic fibrosis neonatal screening (G) https://www.ecfs.eu/files/webfm/webfiles/File/documents/Castellani_2009_
Journal-of-Cystic-Fibrosis.pdf
Sermet-Gaudelus I [3] Guidelines on the early management of infants diagnosed with cystic fibrosis
following newborn screening (G)
http://www.sciencedirect.com/science/article/pii/S1569199310000652
Diagnosis
Mayell SJ [4] A European consensus for the evaluation and management of infants with an
equivocal diagnosis following newborn screening for cystic fibrosis (C)
http://www.elsevier.com/__data/promis_misc/JCF8.pdf
Castellani C [10] Consensus on the use and interpretation of cystic fibrosis mutation analysis in
clinical practice (C)
http://www.elsevier.com/__data/promis_misc/JCF7.pdf
Bombieri C [119] Recommendations for the classification of diseases as CFTR-related disorders (G) https://www.ecfs.eu/files/webfm/webfiles/File/documents/JCF%20Articles/
JCF10_Sup2_S86_S102.pdf
Prevention of progression of lung disease
Döring G [120] Early intervention and prevention of lung disease in cystic fibrosis: a European
consensus (C)
http://www.elsevier.com/__data/promis_misc/2004.pdf
Optimal nutrition and management of metabolic complications
Sinaasappel M [49] Nutrition in patients with cystic fibrosis: a European consensus (C) http://www.elsevier.com/__data/promis_misc/2002.pdf
Sermet-Gaudelus I [61] European cystic fibrosis bone mineralisation guidelines (G) https://www.ecfs.eu/files/webfm/webfiles/File/documents/JCF%20Articles/
JCF10_Sup2_S16_S23.pdf
Treatment of the complications
Döring G [31] Treatment of lung infection in patients with cystic fibrosis: current and future
directions (P)
https://www.ecfs.eu/ecfs-standards-care/references
Colombo C [77] Guidelines for the diagnosis and management of distal intestinal obstruction
syndrome in cystic fibrosis patients (G)
https://www.ecfs.eu/files/webfm/webfiles/File/documents/JCF%20Articles/
JCF10_Sup2_S24_S28.pdf
Debray D [68] Best practice guidance for the diagnosis and management of cystic
fibrosis-associated liver disease (G)
https://www.ecfs.eu/files/webfm/webfiles/File/documents/JCF%20Articles/
JCF10_Sup2_S29_S36.pdf
Heijerman HJ [121] Inhaled medication and inhalation devices for lung disease in patients with cystic
fibrosis: A European consensus (C)
https://www.ecfs.eu/files/webfm/webfiles/File/documents/JCF_article.pdf
Edenborough F [55] Guidelines for the management of pregnancy in women with cystic fibrosis (G) https://www.ecfs.eu/files/webfm/webfiles/File/documents/Pregnancy.pdf
Tranplantation and end of life
Hirche T [86] Practical guidelines: lung transplantation in patients with cystic fibrosis (G) http://dx.doi.org/10.1155/2014/621342
Sands D [87] End of life care for patients with cystic fibrosis (G) https://www.ecfs.eu/files/webfm/webfiles/File/documents/JCF%20Articles/
JCF10_Sup2_S37_S44.pdf
Psychosocial support
Nobili R [108] Guiding principles on how to manage relevant psychological aspects within a CF
team: interdisciplinary approaches (G)
https://www.ecfs.eu/files/webfm/webfiles/File/documents/JCF%20Articles/
JCF10_Sup2_S45_S52.pdf
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of CF is less than 1/7000 births, careful evaluation is required
as to whether NBS is valid. The protocol must be shown to
cause the minimum negative impact possible on the population.
1.2. What health and social resources are minimally acceptable
for newborn screening to be a valid undertaking?
Infants identified with CF through a NBS programme should
have prompt access to specialist CF care that achieves ECFS
standards. A NBS programme may be a mechanism to better
organise CF services, through the direct referral of infants for
specialist CF care. Countries with limited resources should
consider a pilot study to assess the validity of NBS and the
adequacy of referral services for newly diagnosed infants in their
population.
1.3. What is an acceptable number of repeat tests required for
inadequate dried blood samples for every 1000 infants screened?
The number of requests for repeat dried blood samples should
be monitored and should be less than 0.5%. More than 20 repeats
for every 1000 infants are unacceptable (2%).
1.4. What is an acceptable number of false positive NBS results
(infants referred for clinical assessment and sweat testing)?
Programmes should aim for a minimum positive predictive
value of 0.3 (PPV is the number of infants with a true positive
NBS test divided by the total number of positive NBS tests).
1.5. What is an acceptable number of false negative NBS
results? These are infants with a negative NBS test that are
subsequently diagnosed with CF (a delayed diagnosis)
Programmes should aim for a minimum sensitivity of 95%.
Sensitivity is the number of true positive NBS results as a
percentage of the total CF population (true positive and false
negatives). Mechanisms should be in place for the collection of
reliable long-term false negative data.
1.6. What is the maximum acceptable delay between a sweat
test being undertaken and the result given to the family?
The sweat test should be analysed immediately and the result
normally reported to the family on the same day.
1.7. What is the maximum acceptable age of an infant on the
day they are first reviewed by a CF specialist team following a
diagnosis of CF after NBS?
The majority of infants with a confirmed diagnosis after NBS
should be seen by the CF specialist team by 35 days and no later
than 58 days after birth. Programmes that are consistently
missing these targets should undertake a protocol review and
consider alternative strategies.
1.8. What is the minimum acceptable information for families
of an infant recognised to be a carrier of a CF causing CFTR
mutation after NBS?
a) Families should receive a verbal report of the result. They
should also receive written information to which they may
refer later. Information should also be sent to the family primary
care physician.
b) The information should be clear that:
The infant does not have CF.
The baby is a healthy carrier.
Future pregnancies for this couple are not free of risk of CF
and the parents may opt for genetic counselling.
There are implications that could affect reproductive decision
making for extended family members and the infant when they
are of child bearing age.
1.9. What are the minimum acceptable standards for reporting
a CF diagnosis following NBS to the family?
a) A CF Specialist should discuss the result in person with the
parents.
b) The family should receive written information to read after
the consultation. The information should also be sent to the
family primary care physician.
c) The family should have a clear understanding of short and
long term plans with respect to the child's management.
1.10. What are the minimal acceptable standards for the
recognition and management of infants with an equivocal
diagnosis⁎ following NBS?
a) The infant should be reviewed by a CF specialist.
b) This may be in a CF clinic or a non-CF clinic, if local
circumstances are appropriate.
c) Extended gene sequencing should be undertaken when one
or no mutations are recognised.
d) Sweat testing should be repeated in a centre with
considerable experience (N150 sweat tests per annum) and
sweat chloride measured by a standard method.
e) Families should receive clear verbal and written information
about the infant and have a clear understanding of what
to expect with respect to progress and possible symptoms.
Information should also be sent to the family primary care
physician.
2. Diagnosis
Isabelle Sermet-Gaudelus (F)
Kevin W. Southern (UK)
Nataliya Kashirskaya (Rus)
⁎ Deﬁnition; an infant with a repeatedly intermediate sweat test result, or an
infant with two CFTR gene mutations (one of which has unclear phenotypic
outcome) and a normal or intermediate sweat test result. An intermediate sweat
test result is a sweat chloride value between 30 and 59 mmol/L [4].
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It is mandatory to have a high standard of care for diagnostic
evaluation in cystic fibrosis. Diagnostic confirmation is required
not only for children and adults presenting with suggestive
clinical features, but also for infants with a positive newborn
screening test or occasionally a positive family history. The
following statements refer to a diagnosis outside of newborn
screening.
2.1. What are the minimal requirements to undertake the
diagnosis for CF? [5,6]
a) To be able to undertake sweat testing to the standards described
below.
b) To be able to perform genetic testing for the most appropriate
panel for the local population. Access to extended exon DNA
analysis should be available when required.
c) Resources to undertake clinical assessment including
assessment of respiratory condition (respiratory tract culture
for CF-associated pathogens, age appropriate respiratory
function testing and imaging), non-invasive evaluation of
exocrine pancreatic function and sperm count in male adults.
2.2. What are the diagnostic criteria for CF? [5–7]
A sweat chloride above 59 mmol/L
and/or
two CF causing CFTR mutations in trans †
and
at birth or clinical features, including but not restricted
to diffuse bronchiectasis; positive sputum cultures for a
CF-associated pathogen (especially P. aeruginosa); exocrine
pancreatic insufficiency; salt loss syndrome; and obstructive
azoospermia (males).
2.3. What are the minimal standards for laboratories
performing sweat tests? [8]
a) Sweat collection by experienced personnel (at least 150 sweat
tests per annum) following national or international guidelines
and subject to regular (at least annual) peer review. Internal
quality control (usually three samples) of the sweat analysis
with acceptable limits of agreement for chloride before each
sample.
b) Use of a commercially available equipment approved for
diagnostic use.
c) A regular external quality assurance for analytes according
to national guidelines.
2.4. What are the diagnostic standards of a sweat test? [9]
a) The quantity of sweat should indicate an adequate rate of
sweat production (15 μL for Macroduct™ tube system).
b) A sweat chloride value greater than 59 mmol/L is consistent
with a diagnosis of CF.
c) In the first six months of life a sweat chloride value less than
30 mmol/L makes the diagnosis of CF unlikely. There is no
international agreement on the lower limit of the borderline
range after that age, and thresholds of 30 or 40 mmol/L have
been suggested.
d) Individuals with sweat chloride values in the borderline range
should undergo a repeat sweat test and further evaluation in a
CF specialist centre, including a detailed clinical assessment
and extensive CFTR gene mutation analysis [9,10].
2.5. What are the minimal standards for a laboratory
performing mutation analysis for CFTR? [10]
a) The laboratory should be able to perform DNA testing using
dried blood spot samples, whole blood (EDTA) and buccal
swabs.
b) Samples should be analysed at least weekly to avoid
significant delay in processing.
c) The laboratory should partake in an external quality
assurance exercise with at least an annual certification.
d) The primary laboratory should be able to provide a limited
CFTRmutation panel as a starting point that recognises at least
one abnormal allele in more than 90% of the individuals with
CF in a local population.
e) When only one mutation is recognised, an extended exon
DNA analysis (gene sequencing) should be available in a
primary laboratory or a secondary laboratory.
f) The disease liability of variants detected by DNA sequenc-
ing should be validated against the CFTR2.org database.
Novel mutations or variants should be reported to locus
specific databases (such as CFTR1 http://www.genet.
sickkids.on.ca/app) in order to facilitate future interpretation
of variants of unknown clinical significance.
2.6. What is a CF causing mutation?[10]
a) Since CF is an autosomal recessive disease the diagnosis of CF
is substantiated in patients who bear two CF causing mutations
(classified in the CFTR-2 database) in trans (i.e. one on each
homologous chromosome). However, absence of two
CF-causing mutations after extended DNA testing in the
presence of other typical clinical, laboratory features of the
disease or abnormal CFTR bioassays (see below) does not rule
out CF.
b) Patients with “mutations of varying consequence” require
further evaluation in a CF specialist centre.
2.7. What are the minimal acceptable standards of care for
reporting a diagnosis of CF to a symptomatic patient? [2]
a) A positive CF diagnostic test result should be reported
promptly (ideally within 24 h).
b) The patient or parents/carers should receive clear written and
verbal information about the disease and be provided with
access to electronic media from the health service/national
patient organisation. Contact information of the appropriate
† The term “mutation” is synonymous with “pathogenic variant”, according to
the CFTR-2 database http://www.cftr2.org.
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CF centre should be given (in accordance with treatment
pathways for newly diagnosed CF in each country).
c) Genetic counselling should be offered and contacts for clinical
genetic services provided. This will facilitate prevention of CF
in affected families, including their relatives who may have an
increased risk of the disease.
d) An early follow-up appointment should be arranged to
assess understanding (no more than one week) and contact
information of the CF centre should be given.
e) Patients and parents/carers should receive advice on other
information resources, in particular the internet.
f) At the initial diagnostic meeting patients and parents/carers
should receive information about the model for future clinical
care.
2.8. What are the minimal standards of care and follow-up for
a newly diagnosed patient?[5]
A patient diagnosed with CF should have immediate access to
a CF specialist centre which has the multi-disciplinary capacity to
provide care that complies with the ECFS standards of care.
2.9. What are the minimal standards of care and follow-up for
patients with symptoms suggestive of CF and intermediate
sweat chloride values?[5,6]
a) A patient in whom the diagnosis is suggestive of CF and an
intermediate sweat chloride concentration and only one or no
mutation is identified should have access to a CF specialist
centre for an appropriate assessment. It is important that such
patients have long-term care. Follow-up in a clinic other than a
CF clinic may be acceptable in collaboration with a CF
specialist centre.
b) Ancillary tests may help establish a diagnosis of CF by
revealing a second organ disease phenotype, such as pancreatic
insufficiency (faecal pancreatic elastase), CBAVD in males,
lung or sinus involvement, or by identifying an ion channel
abnormality (see section 2.10).
c) These patients must be monitored carefully for development
of any complications and appropriate therapy implementation.
2.10. Should a patient with equivocal diagnosis have CFTR
bioassay tests (nasal potential difference, intestinal current
measurement)? [11]
Patients with a diagnosis that is not clearly CF, should be
assessed by a CF specialist. In cases with intermediate sweat
test results, further electrophysiological investigations (nasal
potential difference, intestinal short circuit current measure-
ment) should be arranged if available.
3. Prevention of progression of lung disease by ensuring all
patients have access to therapies of proven effectiveness
Felix Ratjen (Can)
Patrick Flume (USA)
Alan Smyth (UK)
Life expectancy in CF has improved dramatically in the last
4 decades [12]. However, the majority of CF patients still die of
respiratory failure [13] and so slowing progression of lung
disease is a primary aim of CF therapy. The basic defect of CF
leads to failure of mucociliary clearance, mucus plugging and
secondary infection, with pathogens such as Staphylococcus
aureus and Pseudomonas aeruginosa. Chronic infection
(with neutrophil-driven inflammation) is punctuated by acute
exacerbations, following which lung function may fail to return
to baseline levels [14]. Meticulous daily management of lung
disease, together with prompt, aggressive treatment of exacer-
bations are therefore essential to preserve lung function. Best
practice in this area is discussed in this section.
3.1. Should initial or new bacterial infection with Pseudomonas
aeruginosa be treated?
Left untreated, new infection with P. aeruginosawill progress
to chronic infection which is associated with worse lung function,
worse nutrition, more pulmonary exacerbations and a higher
mortality [15]. There is no clear evidence how quickly an
eradication therapy should be commenced, but treatment should
be started promptly (not more than 4 weeks from receiving a
positive culture result). There is robust evidence that eradication
treatment for P. aeruginosa is effective but no one regimen has
yet been shown to be preferred because of superior efficacy [16].
Options include 28 days of tobramycin solution for inhalation
(TIS) and up to 3 months of a combination of nebulised colistin
and oral ciprofloxacin [17]. Follow-up cultures to document
eradication after treatment are crucial.
3.2. How should chronic bacterial infection with Pseudomonas
aeruginosa be treated?
When eradication therapy has failed, the diagnosis of chronic
infection is made and long term inhaled antibiotic therapy should
be commenced [18]. USA guidelines recommend TIS on alternate
months for patients over 6 years, with chronic P. aeruginosa,
irrespective of the severity of lung disease and continued
indefinitely [19]. Whilst studies are lacking for children younger
than 6 years, treatment at equivalent doses is also recommended in
this age group. The licenced regimen is 300 mg twice daily for
28 days, alternating with 28 days off treatment. A dry powder
inhalation of tobramycin (TOBI PodhalerTM) has been shown to be
of equivalent efficacy [20]. Inhaled aztreonam lysine [21] is
recommended as an alternative by both European and US
guidelines. Colistin (2 MU twice daily) is used widely in Europe
and is now also available as a dry powder preparation [22]. A
specialist physiotherapist should advise on the timing of
inhalational drugs and in an appropriate inhalation technique.
3.3. Is chronic maintenance therapy indicated to treat other
bacteria?
Whilst individual patients may benefit from prolonged courses
of antibiotics, there is currently little evidence to support chronic
maintenance therapy for bacteria other than P. aeruginosa.
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3.4. Is prophylactic therapy indicated to treat bacteria?
Prophylactic flucloxacillin for the first years of life to
prevent infection with Staphylococcus aureus is endorsed by
guidelines in some countries and recommended against in
others; its use remains controversial [17]. There is no evidence
to support prophylactic therapy for other bacteria.
3.5. Is physiotherapy an essential component of chronic
maintenance therapy and is any form of airway clearance superior
to others?
Chest physiotherapy, to achieve airway clearance is advocated
in UK [23] and US [24] guidelines and should be available to all
CF patients. A recent head-to-head trial [25] has shown that
conventional positive expiratory pressure (PEP) is superior to
high frequency chest wall oscillation (which relies on expensive
equipment). However, in most cases there is little evidence to
support the use of one technique over another. The airway
clearance technique should therefore be tailored to the individual
[26]. Flexibility and appreciation of patient preference are
essential when prescribing a suitable airway clearance technique
[27]. The CF specialist physiotherapist should have a compre-
hensive knowledge of all techniques: CF pathophysiology, the
rationale for alternative approaches and any contraindications to
specific treatment techniques [26]. Exercise and physical activity
should be integral to the overall physiotherapy management
suggested for every individual with CF, irrespective of age and
disease severity. Reduction in exercise capacity is associated with
a decline in respiratory function and survival [28].
3.6. What are important components of treating patients during
episodes of clinical deterioration?
a) Early recognition and treatment.
Progression of CF lung disease is characterised by periods of
stability and intermittent episodes of clinical deterioration, termed
pulmonary exacerbations (PEX). There is no agreed definition of
a PEX but it is essential that these episodes are diagnosed and
treated promptly. Patients having change in their symptoms that
could represent a PEX need to have access to a specialised centre
without delay. Necessary diagnostic tools for assessment of PEXs
include lung function measurements, microbiological testing and
radiological tests. Treatment of a PEX usually requires antibiotics
which can be administered orally via inhalation or intravenously.
If the patient needs hospital admission for intravenous antibiotic
therapy it is important that this is not delayed.
b) Multidisciplinary care.
Treatment of CF exacerbations does not rely on antibiotic
therapy alone and requires a multidisciplinary approach. Patients
should be reviewed regularly by a specialist physiotherapist who
will adjust airway clearance and optimise aerosol regimens where
appropriate. Patients often have a reduced appetite and require
increased caloric intake during a PEX, due to higher metabolic
demands. Access to a specialist dietician is crucial. Intravenous
antibiotics should be selected with input from a pharmacist and
infectious disease/microbiology specialist.
c) Antibiotic regimen.
The pharmacokinetics of antibiotics differ between CF and non
CF individuals and antibiotic dosages need to be adjusted
according to disease specific guidelines (including higher doses
in some cases) [29]. For P. aeruginosa, a combination of two or
more antibiotics is recommended and, although evidence is
lacking, 14 days of intravenous treatment is routine [30]. Some
patients may benefit from longer therapy and this decision should
be based on medical needs rather than resources and costs. Home
intravenous antibiotic therapy is used in individual cases, but a
home care programme needs to assure that all aspects discussed
above are part of the treatment plan. Therefore hospital treatment
remains the standard of care for most patients requiring intravenous
antibiotic therapy.
d) Evaluating response to therapy.
It is important to monitor lung function at the beginning and
end of treatment of a PEX. Despite intensive treatment about
25% of patients experiencing a PEX requiring intravenous
antibiotic therapy will have a persisting decline in lung function
[14], emphasising the need for maintenance therapies to prevent
exacerbations.
3.7. What are the recommended chronic maintenance therapies
to maintain lung health?
A comprehensive review of this topic is beyond the scope of
this document and is available elsewhere [19,31]. Airway clearance
techniques, physical activity and nutritional support are important
components in maintaining lung health; here we focus on drug
therapy only.
3.7.1. Mucolytics
The only mucus degrading agent that has proven efficacy in CF
is dornase alfa. Studies have demonstrated improvements in lung
function and a reduction in pulmonary exacerbations in patients
regardless of disease severity [32]. Recent evidence from an
analysis of a large data base suggests that dornase alfa reduces
lung function decline [33]. Treatment effects are lost when
treatment is ceased, therefore long term maintenance therapy is
required. Other mucolytics, such as N acetyl cysteine, have not
been proven to be effective in CF patients [34].
3.7.2. Hydrator therapy
Airways in CF are dehydrated and increasing the airway
surface liquid can be accomplished with osmotic agents that are
called hydrators. The mechanism of action differs from that of
dornase alfa and both approaches are complimentary. Hypertonic
saline and mannitol are available as inhaled agents in Europe.
Hypertonic saline (7%) has been shown to reduce pulmonary
exacerbations and marginally improve lung function in a
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systematic review [35]. H ypertonic saline is currently used in
many patients with moderate to severe lung disease and is
supported by guidelines [19]. Mannitol has been introduced more
recently and improves lung function [36,37]. The drug is
available as a dry powder formulation thereby reducing treatment
time. Both agents act as irritants and require pre-treatment with a
bronchodilator and initial tolerability testing.
3.7.3. Antibiotic therapy
Airway infection in CF can be divided into early, intermittent
and chronic infection. This scheme has been useful for
P. aeruginosa infection (see question 1 above) and may also
apply to other bacteria. If eradication fails and chronic infection
with P. aeruginosa develops, inhaled antibiotic therapy has
proven efficacy to reduce pulmonary exacerbations, improve lung
function and respiratory symptoms [18] and is therefore part of
standard of care [17,19]. Inhaled antibiotic therapy should be
administered as long term maintenance therapy with either single
agent therapy or alternating therapy of different antibiotics. The
benefits of treatment outweigh the risks associated with the
development of antimicrobial resistance which is often overcome
by high topical antibiotic concentrations.
3.7.4. Macrolides
Macrolides are beneficial to CF patients likely due to their
dual effect on infection and inflammation. Whilst not primarily
efficacious against P. aeruginosa, there is evidence suggesting
efficacy if the organism resides in biofilms which is the case in
chronic P. aeruginosa infection. Maintenance therapy with
azithromycin has been shown to improve lung function and
reduce PEXs in chronically infected patients [38] and is part of
recommended care [19]. A reduction in pulmonary exacerbations
has also been observed in younger patients not infected with
P. aeruginosa [39]. Some concerns remain, regarding the dur-
ability of their effect and their impact on inducing resistance for
other bacteria.
3.8. Is airway inflammation a target of chronic maintenance
therapy and how should it be treated?
Inflammation is an important component of CF lung disease.
CF airway inflammation is neutrophil dominated and common
anti-inflammatory drugs such as corticosteroids, either systemic
or inhaled have no proven efficacy in CF patients, outside of
treatment of concomitant asthma. High dose ibuprofen has been
shown to reduce lung function decline [40]. Treatment requires
monitoring of drug levels and despite these promising data it
has not received widespread acceptance. Whilst other anti-
inflammatory therapies are currently being studied, they are
neither supported by sufficient evidence nor available for clinical
care at the present time.
3.9. CFTR modulator therapy — which treatments address the
underlying defect in CF?
Current treatment largely addresses the symptoms caused by
the defective gene whilst CFTR pharmacotherapy aims to increase
protein expression at the cell surface, or its function, with drug
therapy. This treatment strategy could make a major difference in
altering or even halting the disease process. Different drugs
targeting specific classes of CFTR defects are currently being
studied; to date only one drug has clearly demonstrated clinical
efficacy. Ivacaftor, a CFTR potentiator studied in the gating
mutation G551D, not only enhanced ion transport reflected by
reductions in sweat chloride concentrations but also improved
clinical measures such as lung function and PEXs [41]. The effect
size of lung function changes exceeded that observed for any drug
therapy available for CF patients to date. Whilst this mutation is
found in less than 5% of patients worldwide, ivacaftor is a proof of
principle demonstrating the potential impact of CFTR pharmaco-
therapy. In patients with the G551D mutation ivacaftor should be
part of standard of care.
3.10. How should fungal infections and severe/recurrent
Allergic Bronchopulmonary Aspergillosis (ABPA) be treated?
Aspergillus fumigatus as well as other fungi are commonly
found in sputum of CF patients. Whilst their relevance is not
entirely clear, more recent evidence suggests that A. fumigatus
may act as a pathogen in at least in some CF patients [42].
Sputum cultures in CF patients should therefore include
assessments for fungi. Allergic bronchopulmonary aspergillosis
is a well characterised complication in CF patients and should
be considered in any patient with clinical deterioration not
responding to antibiotic therapy [17]. Diagnostic tests include
allergy skin testing, measurements of serum IgE and IgE
specific to Aspergillus, and serum precipitins for Aspergillus.
These tests need to be available to every CF care facility.
Treatment is with oral prednisolone plus/minus antifungal
therapy [17].
3.11. How should we monitor lung disease?
• A multi-disciplinary team is needed to assess and discuss all
aspects of CF care.
• Regular monitoring includes assessment of competence of
airway clearance and inhalation technique and monitoring of
adherence.
• Clinical assessments that should be performed at least every
3 months and at times of symptomatic deterioration [43].
• As airway infection is a major driver of CF lung disease
airway cultures should be obtained at every clinic visit [17].
The microbiological assessment needs to include specific
culture media for the range of CF pathogens to ensure that
relevant organisms are not overlooked.
• Lung function testing guides therapy and should be performed
at every clinic visit in patients old enough to cooperate (usually
5 years and older) [43]. Tests for younger children are currently
under development. Routine lung function testing should
include spirometry performed according to ATS/ERS criteria
[44] and testing pre and post bronchodilator should be available.
Chest X-rays are routinely performed on an annual basis in
most CF centres as well as at times of clinical deterioration.
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Other imaging modalities such as high resolution CT scanning
should be available as well and are used routinely in some CF
centres.
4. Optimal nutrition and management of metabolic
complications of cystic fibrosis
Anne Munck (F)
Sarah Jane Schwarzenberg (US)
Sue Wolfe (UK)
Nutritional status has a strong positive association with
pulmonary function and survival in CF. Attainment of normal
growth in children and maintenance of adequate nutrition in
adulthood represent major goals for the CF team.
4.1. What are the goals for nutritional status in patients with
CF?
Infants and children should grow normally, with infants
achieving normal weight and height percentiles similar to
the non-CF population by two years of age. Older children and
adolescents should achieve the 50th percentile for body mass
index (BMI). In adults absolute BMI should be maintained above
20 kg/m2, ideally, 22 kg/m2 (females) and 23 kg/m2 (males). All
patients should have normal fat soluble vitamin andmicronutrient
status. Essential fatty acid status should be monitored, if the assay
is available. Guidelines have been published on nutritional
evaluation and management [3,5,45–51].
4.2. How do we monitor nutritional status in routine care?
Until growth ceases, accurate measurement of weight (kg),
length or height (m), and head circumference (cm) (up to
2 years of age) should be made at each hospital visit. In adults,
height should be measured annually. Measurements should be
converted to BMI (N2 years) and compared to national
reference charts. Special attention is needed for toddlers and
adolescents due to rapid growth velocity [3,43,45–53].
4.3. How do we determine exocrine pancreatic insufficiency
(EPI) and adequate pancreatic enzyme replacement?
Confirmation of EPI is required. Coefficient of fat
absorption (CFA) is the “gold standard”, but is cumbersome.
Faecal pancreatic elastase-1 (FE1) is simple and reliable from
two weeks of age in the absence of liquid stools.
Pancreatic sufficient patients should be monitored by annual
FE1 during infancy and childhood and during periods of failure
to thrive, weight loss or diarrhoea.
Pancreatic enzyme replacement therapy (PERT) adequacy is
determined clinically, monitoring nutritional status, signs and
symptoms of malabsorption and excessive appetite with poor
weight gain. Inappropriate doses of PERTmay result in abdominal
pain and constipation.
Guidelines for testing for EPI and dosing of enzymes are
available [3,46–51,54].
4.4. What are the main strategies to providing preventive
nutritional care?
CF centres should be familiar with the recommendations for
age-appropriate dietetic advice directed by CF dietitians
[3,5,43,45-51,54–56]. This includes:
• Assessment of EPI and administration of PERT.
• Selection of appropriate diet, with attention to a high fat
intake.
• Behavioural therapy to achieve positive mealtime experiences.
• Providing sodium supplementation, when necessary, with
special awareness in newborn screened infants.
• Supplementing fat soluble vitamins, as indicated by laboratory
testing.
Women with CF who plan their pregnancies should receive
pre-conception advice to improve their nutritional status [55].
4.5. What factors should be evaluated in patients with poor
growth?
Evaluation should be triggered by weight loss, or decline in
weight or length/height percentile (b2 years of age), or decline
in BMI percentile for age and gender (N2 years of age), or poor
linear growth (b18 years) or decline in BMI (N18 years). Early
intervention is essential to avoid significant loss of weight or
growth.
Diagnosing the cause of malnutrition relies on a careful
assessment and a multidisciplinary approach. Potential causes
include insufficient food intake, excessive stool energy losses
(inadequate PERT or poor adherence), Giardia infection, coeliac
disease, hypercatabolism from pulmonary disease, vomiting or
gastroparesis, glycosuria and psychological impacts of CF.
4.6. What are the options for interventional nutritional care?
Interventions should be tried stepwise for a limited period of
time or until nutritional status is optimised, depending on the
severity of malnutrition and the age of the patient.
• Anticipatory guidance. Reinforcement of adherence to diet,
sodium and enzyme recommendations, using behavioural
modification or motivational interviewing
• Moderate malnutrition. Oral supplements should be used as
additional calories in a time-limited trial or temporarily as
meal replacement for ill patients. Temporary nasogastric
(NG)/nasojejunal (NJ) feeds may be useful
• Severe malnutrition. Enteral feeding via NG or gastrostomy
tubes usually improves and maintains nutrition in a patient
with CF
Other therapies: Cyproheptadine and growth hormone are
not part of routine management. Parenteral nutrition is only
appropriate when enteral nutrition is impossible or fails.
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Nutritional rehabilitation can take 3–6 months, so if being
used pre-operatively should start well ahead of an anticipated
operation (e.g. organ transplantation) [45–49,56].
4.7. When and how do we screen for diabetes mellitus?
All CF patients who have not been diagnosed with diabetes/
CFRD including those who may have had gestational diabetes
should be screened during a period of clinical stability using the
standard WHO protocol annually from age 10 years. A single
abnormal OGTT requires confirmation with a second test.
Refer to the published guidelines for additional detail.
Published guidelines [57–59] suggest more frequent screen-
ing with fasting/post-prandial glucose and/or OGTT in the
following situations: pulmonary exacerbation, initiation of
glucocorticoids, enteral tube feeding, planning for pregnancy,
during pregnancy, planned organ transplantation and where
there are symptoms of diabetes.
4.8. What is the current management of CFRD?
Care of patients with CFRD should adhere to standards of
care for all individuals with diabetes; specific variations
required for patients with CF are outlined below [57–59].
Patients with CFRD require care from a multi-disciplinary
management team with experience in CFRD and in communi-
cation and consultation with the CF team. It is recommended that
CFRD be treated with insulin, not oral diabetic agents. Glucose
control may be challenging during pulmonary exacerbations,
requiring more frequent monitoring and increased insulin. CF
nutritional guidelines apply to CFRD patients. Modification of
calorie, fat, protein, or salt intake as a result of the diagnosis
of diabetes is not appropriate. Monitoring for complications of
CFRD is similar to that for other forms of diabetes. CF patients
with impaired glucose tolerance (IGT) must be monitored
closely, particularly when ill, as they may need insulin therapy
intermittently.
4.9. Should patients be screened for CF bone disease and if so,
how and which factors are involved in the prevention of
reduced bone mineral density?
Low bone mineral density (BMD) is a common complica-
tion in adolescent and adult patients and can occur in children
as clinical status declines. Routine screening for reduced BMD
using dual energy X-ray absorptiometry (DXA) scans from the
age of eight to ten years is recommended, as detailed in
published guidelines [60–62].
Centres should be familiar with the factors contributing to
development of reduced BMD in CF and how to reduce these
risks. The most common risk factors include: pulmonary
infections, poor nutritional status and lack of weight bearing
exercise, delayed puberty, glucocorticoid treatment, hypo-
gonadism, and vitamin D, calcium and vitamin K deficiencies
[60–62].
4.10. What is the current management of reduced bone mineral
density?
Known risk factors should be minimised and dietary intake of
calcium and vitamin D should be optimised to enhance bone
health. The use of bisphosphonates should be considered on an
individual basis, taking bonemineral density, low trauma fracture
history and transplant status into consideration [60–62].
5. Treatment of the complications of cystic fibrosis in a
timely and effective way
Patrick Flume (USA)
Giovanni Taccetti (It)
Alan Smyth (UK)
5.1. Pulmonary complications
Patients with cystic fibrosis (CF) may develop a variety of
complications which, although infrequent, occur commonly
enough that the CF centre should be well-prepared in their
management. The following offers standards of diagnosis and
management for these complications as well as resources for
additional guidance.
5.1.1. What is the best way to manage pneumothorax in
patients with CF?
Pneumothorax is a complication occurring more commonly in
patients with more severe obstructive airways disease [63]. The
CF centre should have a high suspicion for this complication in
the patient with acute chest pain and shortness of breath and be
able to make the diagnosis using radiologic studies (i.e. chest
X-ray, CT chest). Management guidelines have been published
[64]; the Centre should be able to provide basic treatment (i.e.
chest tube, pain control). For those patients who may need more
complicated procedures (e.g. VATS), the Centre should have
pre-agreed referral process with Thoracic Surgery Services.
5.1.2. What is the best way to manage hemoptysis in patients
with CF?
Hemoptysis is a common complication and may range in
severity from scant to massive, defined as N240 ml/day or
N100 ml/day for several days [65]. Management guidelines have
been published [64]. The Centre should give the patient and
family clear guidance about when to call, if hemoptysis occurs,
and should be able to provide the recommended therapies. For
severe bleeding, the Centre should have access to interventional
radiology (e.g. bronchial artery embolisation) and/or thoracic
surgery.
5.1.3. What is the best way to manage respiratory failure in
patients with CF?
The natural history CF lung disease is progression to
advanced stage airways obstruction and eventual respiratory
failure. The Centre should recognize progression to this stage
and have discussions about lung transplant and advanced
healthcare directives (see Section 6). The need for supplemental
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oxygen should be assessed in the patient with advanced stage
lung disease (FEV1 b 40% predicted) both at rest and with
exercise [56]. Ventilatory support (e.g. non-invasive ventila-
tion) should be provided in accordance with the patient's
wishes for palliation of dyspnea [43]. The Centre should be
able to assess the need for opiates to relieve dyspnea and pain
associated with advanced stage disease [66,67].
5.2. Liver and pancreas complications
5.2.1. What is the best way to manage liver disease in patients
with CF?
Many pancreatic insufficient (PI) CF patients will have
evidence of liver disease ranging in severity from very mild
biliary fibrosis to end-stage cirrhosis. Cystic fibrosis related liver
disease (CFLD) is a biliary cirrhosis that usually presents before
age 20 years and can lead to portal hypertension and hepatic
failure [68,69]. The Centre shouldmonitor all patients with routine
physical examination and periodic liver enzyme testing. Guide-
lines on the use of ultrasonography, ursodeoxycholic acid
(“Urso”), and when to consider a liver biopsy, are available in
published guidelines [68–70].
Patients with portal hypertension should be referred to a
gastroenterologist/hepatologist for screening endoscopy and
management of complications of pulmonary hypertension.
Routine management of CF patients with cirrhosis should include
immunisation against hepatitis A and B viruses, avoidance of
NSAIDs and hepatotoxic agents (e.g. alcohol), and monitoring of
the functional status of the liver (i.e. coagulation, albumin). The
Centre should have a pathway for referral to a liver transplant
programme, for those patients with advanced stage liver disease.
5.2.2. What is the best way to manage cholelithiasis in patients
with CF?
Cholelithiasis is not always symptomatic [71]. The Centre
should be suspicious when evaluating the patient with non-
specific abdominal pain and nausea. The Centre should have
access to ultrasonography and HIDA scan for assessment of the
gallbladder. For symptomatic gall stones, ursodeoxycholic acid is
ineffective and surgical referral is usually necessary.
5.2.3. What is the best way to manage pancreatitis in patients
with CF?
Pancreatitis is a less common complication in the CF
population, but troublesome in some CF individuals with
pancreatic sufficiency [72]. Recurrent acute pancreatitis may
contribute to the transition from pancreatic sufficiency to
insufficiency in CF. The presentation may be a nonspecific
abdominal pain, so there should be a high suspicion when seeing a
patient with a recurrent, unexplained pain and associated nausea
and vomiting. The Centre must be able to evaluate with standard
laboratory testing (i.e. amylase, lipase) and imaging (e.g. ultra-
sonography, CT, or MRI). Management principles are not
different than for non-CF pancreatitis. However, acute pancreatitis
is associated with severe dehydration and in the CF population,
this may be more severe and attention to rehydration and
electrolyte monitoring is crucial.
5.3. Gastrointestinal complications
5.3.1. What is the best way to manage gastroesophageal reflux
disease (GORD) in patients with CF?
GORD occurs commonly in patients with CF, affecting
approximately 30% [73]. The Centre should be aware of the
signs and symptoms of GORD and be able to provide appropriate
diagnostic testing (i.e. impedance and pH probe, upper endosco-
py) and treatment [74].
5.3.2. What is the best way to manage constipation in patients
with CF?
Constipation has a slow onset with reduced stool frequency
[75]. It is common in CF and may be exacerbated by the use of
narcotics. Most of the time constipation responds to hydration
therapy, stool softeners (e.g., polyethylene glycol) or laxatives
[76]. Enemas are rarely needed.
5.3.3. What is the best way to recognize and manage distal
intestinal obstruction syndrome (DIOS)?
The symptoms of DIOS have acute onset with right lower
quadrant pain [75]. The Centre should be able to recognise this
complication (and its variants) and have standard protocols for
diagnosis and treatment based upon published recommendations
[43,75,77]. Patients may respond to oral rehydration combined
with stool softeners, but more severe cases may require IV
hydration, nasogastric aspiration, and enemas. For patients who
fail such conservative therapies, referral to a gastroenterologist
with knowledge of DIOS is essential. Surgical intervention should
be considered only in extreme situations and so the Centre should
have surgeons who know about the gastrointestinal complications
of CF.
5.3.4. What is the best way to prevent fibrosing colonopathy
(FC)?
This is an uncommon complication. The only clear recom-
mendation to prevent FC is to use the appropriate dose of
pancreatic enzymes, not increase enzyme dose without clear
indication and not exceed 10,000 lipase units/kg/day total enzyme
dose [49].
5.3.5. What is the best treatment for appendiceal mucocele?
Ultrasonography will aid the diagnosis [78]. In case of
symptoms, appendectomy with resection of the appendix edges
and resection of the caecal tip will avoid risk of recurrence.
5.3.6. What is the best way to manage small bowel overgrowth
in patients with CF?
Small bowel overgrowth is suspected when patients have
diffuse or periumbilical abdominal pain, excessive bowel gas,
nausea, and malabsorption despite adequate enzyme intake. Risk
is higher in patients who have had previous intestinal surgery or
are using narcotics. It is recommended that diagnosis be made by
clinical therapeutic trial of metronidazole [79]. An opinion from a
gastroenterologist is essential.
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5.3.7. What is the best way to manage meconium ileus (MI) in
patients with CF?
MI is a neonatal emergency best handled by a pediatric
surgeon (and pediatric radiologist) with expertise in MI, who
should liaise promptly with the CF centre. The surgical team
should be familiar with both non-surgical and surgical manage-
ment [80,81]. Complicated MI is more severe, more difficult to
treat, and may require prolonged hospitalisation. Post-operative
management may require a centre familiar with nutritional
management of short bowel syndrome.
5.4. Other complications
5.4.1. What is the best way to manage medication toxicities?
The treatment of CF lung disease can result in complications
due to the treatment and toxicity related to medications, especially
aminoglycosides (e.g. nephro-, oto-, and vestibular toxicity).
The Centre should utilise standard protocols for therapeutic
drug monitoring when using aminoglycosides following
recommended treatment dosing [17]. There should be strict
avoidance of NSAIDs when using intravenous (IV) aminogly-
cosides to avoid nephrotoxicity. The Centre should perform
assessment for ototoxicity using audiology testing for patients
who have hearing loss or tinnitus, or as part of a routine
screening assessment. The Centre should have access to a
clinician experienced in vestibular assessment.
5.4.2. What is the best way to manage nephrolithiasis in
patients with CF?
Nephrolithiasis is common in CF patients [82]. The Centre
should be aware of the signs and symptoms associated with
nephrolithiasis and able to evaluate by urinalysis and CT-IVP.
The metabolic disorder causing kidney stones should be
determined. The Centre should have access to a urology
specialist and interventional radiologist for complicated
nephrolithiasis.
5.4.3. What is the best way to manage arthropathy in patients
with CF?
Arthralgias are common symptoms in CF patients [73] but
arthropathy remains poorly understood. The Centre should be
aware of this problem and have access to a rheumatologist who
has knowledge of CF.
5.4.4. What is the best way to manage sinus disease in patients
with CF?
Chronic sinusitis with or without nasal polyposis is common in
patients with CF [73]. The Centre should routinely evaluate sinus
disease and offer a recommended treatment, recognizing that this
could be a source for lower airways infection [83]. The Centre
should have access to diagnostic testing (i.e. CT sinus) and to an
otolaryngologist experienced with CF-related sinus disease.
5.4.5. What is the best way to manage allergic disease in
patients with CF?
With the exception of ABPA, discussed elsewhere in this
document, the prevalence of allergic disease is not increased in
CF patients and can be managed as for the general community.
However patients can develop drug allergies (e.g. antibiotics)
that can complicate treatment decisions. The Centre should be
aware of the signs and symptoms of possible allergic response
to treatment and should know when to stop that therapy
accordingly. The Centre should have established protocols for
desensitisation.
5.4.6. What is the best way to avoid complications that result
from chronic indwelling intravenous (IV) catheters in patients
with CF?
An indwelling IV catheter should be placed in accordance
with the patient's wishes if difficulties exist in performing IV
treatment. The Centre should have access to professionals
experienced in the placement of indwelling catheters (e.g.
Port-A-Cath). Only trained individuals should access the
indwelling catheter, using standardized protocols in infection
control and maintenance of the catheter. Common complica-
tions of catheters include vascular problems (e.g. infection,
thrombus, SVC syndrome) [84,85]. The Centre should have a
keen awareness of the signs and symptoms of catheter-related
complications and be able to perform proper testing including
blood cultures (to assess for infection), ultrasonography and
contrast radiology studies (CT or MRI) for vascular occlusion.
5.4.7. What is the best way to address pregnancy in a CF
patient?
Pregnancy can complicate themanagement of womenwith CF.
The Centre should always inquire about possible pregnancy when
assessing womenwhomay be fertile, especially when considering
additional medications that are contraindicated in pregnancy. The
pregnant CF patient should always be considered as having
high-risk pregnancy because of the potential pulmonary and
nutritional/metabolic complications and should be seen by an
obstetrician experienced in high-risk cases. Management recom-
mendations for pregnant CF patients have been published [55].
5.4.8. What is the best way to address infertility in a CF
patient?
Females with CF can become pregnant and those with good
lung function and nutrition are likely to complete the pregnancy.
In less well females there is the possibility of reduced fertility,
and they should be referred to specialists in fertility services if
there is a perceived inability to become pregnant. Most (98%) CF
males will be azoospermic and should be informed of this finding
at an appropriate age. Sperm analysis should be offered to those
patients interested in knowing their status. Patients should receive
proper counselling regarding fertility options including assisted
reproductive techniques.
6. Transplantation and appropriate management of end of
life issues
Scott Bell (Aus)
Alistair Duff (UK)
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6.1. Summary
Transplantation is an established therapy for end-stage lung
and liver disease in patients with CF. Referral to transplant
services is enhanced by the CF team having an understanding of
the processes leading to a success transplant. In some patients,
transplant is not a suitable treatment option or does not occur.
Effective management of the end of life is vital and requires
attention to communication, symptom control and a multi-
disciplinary approach to care, including expertise in palliative
care. These standards include a series of questions about the
approach to transplantation assessment and end of life care,
utilising available published evidence and published transplant
guidelines. For a detailed review of all facets of the topic see
“Practical guidelines: Lung transplantation in patients with
cystic fibrosis” prepared by the European Centres of Reference
Network for Cystic Fibrosis (ECORN-CF) Study Group [86] and
the ECFS End of Life Care Guidelines [87].
6.2. Questions
6.2.1. What are the important determinants for the timing of
listing for lung transplantation in patients with CF?
The lead time for assessment and waiting for suitable donor
lungs is variable but can be in excess of two years. Factors that are
associated with increased mortality [88,89] and where transplan-
tation referral [89] is recommended are in patients with:
• FEV1% predicted of ≤30% predicted,
• Rapid decline, particularly female and younger patients,
• Oxygen therapy for hypoxaemia,
• Hypercapnia,
• Frequent exacerbation that responds poorly to intravenous
antibiotics.
Earlier referral should be considered in patients with refractory
pneumothorax and recurrent massive haemoptysis [89]. In-
creased survival, limited donor availability and differences in
organ allocation schemes have led to prediction models of
mortality/survival which assist with decisions for prioritising
patients for transplantation [90,91]. The complexities of timing
transplantation-referral require close liaison with the Transplant
Service. This will also help patients process complex information
and make informed choices.
6.2.2. What clinical features increase the risk for dying on the
lung transplant waiting list?
Priority for transplantation [88,89,92] should be given to CF
patients with:
• Oxygen-dependent respiratory failure,
• Chronic hypercapnia,
• Pulmonary hypertension,
• Undernutrition, especially female patients.
The limited donor pool determines the number of possible
transplants. National policies optimise the efficiency of donor-
organ allocation differently, depending on donor identification
systems and practical/geographical logistics. Prioritisation of
urgent cases is managed at a national level.
Regular and detailed communication with the Transplant
Service is vital to allow regular updates of the clinical progress
of all wait-listed patients.
6.2.3. What are the important patient variables, which may
prevent active listing for lung transplantation in CF?
Exclusions for lung transplantation [89] include:
• Malignancy within 2 years. A disease-free period of 5 years
is generally required. Consideration for cutaneous and some
urogenital cancers may be given
• Untreatable dysfunction of another major organ (e.g. heart,
liver, kidney),
• Chronic extra-pulmonary infection (e.g. hepatitis B, hepatitis C,
HIV),
• Severe skeletal deformity,
• Prolonged poor-adherence or irregular clinic attendance,
• Untreatable psychological condition/s limiting ability to
participate with therapies,
• Lack of consistent social support system,
• Substance addiction (e.g. alcohol, tobacco, within previous
6 months).
Most transplant services do not assess patients with:
• Chronic Burkholderia cenocepacia
• Mycobacteria abscessus.
Other infections (e.g. multi-resistantPseudomonas aeruginosa,
Scedorsporium species, Clostridium difficile) are influenced by
local transplant unit policy and experience and require detailed
discussion.
Combined ‘liver/lung’ or ‘lung only’ transplantations require
careful consideration in patients with advanced lung disease and
portal hypertension.
6.2.4. What complications of CF are important to prioritise
prior to lung transplantation?
Optimising nutritional status is a priority for wait-listed
patients, but should not be a strong factor in delaying the listing
process [92].
CFRD is present in 40–50% of patients at assessment and
develops post transplant in another ~20% of patients. Increased
mortality, infection and rejection-related hospitalisation have been
reported in patients with CFRD at transplantation. Optimising
control of CFRD is important whilst wait-listed [93,94].
Chronic kidney disease (CKD) occurs in many adults with CF
and where practical, limiting exposure to nephrotoxic drugs
pre-transplant should be considered [95]. The impact of long-term
systemic use of aminoglycosides before transplantation on post-
transplant renal function is uncertain [96]. Calcineurin inhibitors,
hypertension and CFRD have been associated with CKD follow-
ing transplantation.
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Osteoporosis (24%) and osteopenia (38%) is reported in
patients with CF [97]. Biphosphonate therapy may be required
to maintain and improve bone health pre-transplantation.
Systemic corticosteroids are required in some patients with
advanced lung disease (e.g. APBA). Limiting daily dose of
prednisolone to b15 mg/day will assist in healing and reduce
post-operative infection risk and limit further reduction in bone
density.
Psychologically it is vital to help patients maintain hope and
counter demoralisation or exhaustion.
6.2.5. Under what circumstances should invasive ventilation be
considered in patients with CF?
The role of invasive ventilation for patients with end-stage
pulmonary disease is controversial and associated with poor
outcomes [98].
Consideration should be made for patients who develop res-
piratory failure in the setting of an acute precipitant and where
recovery is anticipated (e.g. massive haemoptysis, pneumotho-
rax, influenza, post-operative care) [98,99].
Transplantation from the ventilator is associated with higher
early mortality [100] and is only offered in highly selected cases
and not by all transplant services. Usually this only occurs in
patients who have completed transplant work-up prior to
ventilation.
Some transplant services consider transplantation in patients
who have required Extracorporeal Membrane Oxygenation
(ECMO) for severe respiratory failure. Case reports have
suggested excellent outcomes [101]. Close communication
between the CF Team and the Transplant Service is mandatory
prior to ECMO initiation.
6.2.6. What therapeutic modalities are important in the
palliative care of the patient with CF?
Early discussions (including the potential for transplantation)
to allow time to psychologically adjust and carefully consider
options is required, particularly as misunderstanding is common.
The physician should initiate a conversation about end of life
care with the patient and family and should involve the multi-
disciplinary team. Significant psychological intervention can be
required (e.g., management of anticipatory grief and work with
family members) [102].
Symptoms that frequently require control include dyspnoea,
chest pain, headaches, fatigue and poor sleep quality [103]. The
use of narcotic analgesic, anxiolytics, airway clearance support,
psychological strategies, oxygen and non-invasive ventilation
support are important [67]. Teams should access support from
palliative care colleagues to optimise symptom control, when
required [103,104].
The balance between effective active treatments whilst
providing adequate symptom control can be difficult especially
in patients waiting for transplant [103,105]. Symptom control
does not preclude lung transplantation, however close commu-
nication between CF and Transplant teams is vital [103].
The death of a patient can have a significant effect on other
patients and staff at the centre. Support of other patients with
CF and staff members should be offered [103].
6.2.7. What factors are important in deciding on the location of
care for the dying person with CF?
Patients' and families' wishes should be the key to making
decisions about where to manage the dying patient and where
practical, measures taken to assist facilitating these wishes. The
support available at home to optimally manage all symptoms is
a key consideration (e.g., providing airway clearance support,
the availability of timely symptom control).
Patients prefer to have care by a staff that they know well in
a familiar environment [106] and, in many cases, prefer to
receive care in a hospital [103,107].
Active management of patients to maximise symptom
control often continues and potential for conflict between active
management and optimising control symptoms needs to be
carefully considered.
Communication between all team members, community
healthcare team (including primary care), the patient and the
family are vital.
6.2.8. How should CF-specific complications be managed
following recovery from lung transplantation?
After lung transplant, management of complications of CF
remains important (e.g. CFRD, osteoporosis, DIOS). In many
cases, the transplant service manages the complete care of the
patient. However, the CF Centre should be available to support
where assistance is desired.
Psychosocial input is required to address psychopathology
(e.g. drug-related psychosis, post-traumatic stress reactions).
7. Psychosocial support
Alistair Duff (UK)
Gerald Ullrich (Ger)
Mandy Bryon (UK)
Living with CF can be emotionally and physically challenging
for the patient with CF and their relatives. The condition and its
treatment influence the ability to deal with normal tasks of daily
living and unexpected life events. Good psychosocial care is now
well-integrated into the medical team and there is a substantial
body of literature that establishes the essential elements of the
psychosocial role [5,108]. The focus of this paper is to prioritise
key psychosocial issues and make recommendations for appro-
priate management.
7.1. What are the core elements of supporting parents in the
first year, post-diagnosis?
Diagnosis of CF for the majority is by newborn screening.
Screening for CF aims to minimise morbidity and mortality, yet
potential disadvantages must be recognised and effects minimised
[2]. Diagnosis of CF is traumatic, especially in an otherwise
healthy infant. Parents can experience disbelief and dissociation
from the diagnosis and baby, which can last well beyond the first
few weeks [109]. Preventative counselling and emotional support
must be offered to assess parents' (i) understanding of informa-
tion, (ii) reactions to diagnosis and, (iii) coping style, support
needs and resources.
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Parents need to engage in education about their child
growing up with CF, ensuring balance between managing a
complex health condition and enabling their child to grow with
good self-esteem and concept. Families should be hopeful that
their child will enter adulthood having a good quality of life
with achievements similar to non-CF peers.
Key tasks are to advise on:
• Establishing treatment with baby's daily-routine
• Helping parents accept and administer treatment
• Communicating to family and friends about the medical
condition
• The availability of psychosocial follow-up for parents if
required including couple counselling
• Available financial support/benefits/allowances and other
sources of support.
7.2. International Depression/Anxiety Epidemiology Study
(TIDES)
European data emerging from the International Depression/
Anxiety Epidemiology Study (TIDES) show that elevated
depression scores are no different to general populations although
higher anxiety scores have been reported, particularly amongst
women. Several risk factors have emerged for increased
depression and anxiety scores amongst patients. Anxiety and
depression also appear particularly problematic in parents.
Support for these problems should be available from the CF
service. In what ways should they be identified and addressed?
The CF team needs to assess the psychological well-being of
people with CF routinely (see Centre Framework for access to
psychological professionals). Surveillance for depression and
anxiety in patients and parents should be conducted during annual
review with psychometrics (e.g. HADS, CES-D) or discussion.
Elevated psychometric scores require diagnostic confirma-
tion. This should be undertaken by the CF Team psychologist
via clinical interview. Where there is no integrated psycholo-
gist, referral should be considered to mental health agencies.
Psychological intervention when required, needs to be
supported with consideration of the practical, social, educa-
tional and vocational needs of the patient and their caregivers.
7.3. How do we promote psychosocial resilience at key
transition points and address potential associated psychosocial
vulnerability?
Transitions relate to significant changes in developmental
and personal prospects and challenges for people with CF and
the sense of responsibility these imply.
Key transition points are:
i. Parental adaptation to diagnosis
ii. Commencement of schooling; nursery, primary and
secondary
iii. Parental- to self-guided treatment
iv. Transition of care from paediatric to adult services
v. Entering the workplace or further education
vi. Loss of independence (e.g. retirement, loss of activities and
functioning, increased reliance on intrusive treatments and
carers, and facing transplantation or end of life).
Psychosocial resilience is broadly an ability to recover from
negative events with an absence of lasting emotional distur-
bance. It is multi-factorial, the elements of which are not all
amenable to change [110]. The primary focus should be to
increase social support and foster hope (primarily by paediatric
preparation of patients for fulfilling adult lives and increasing
self-efficacy and control). Emotional vulnerability should be
addressed pro-actively at each transition point.
7.4. What are the core components in addressing adherence,
particularly to nebulised therapies?
Improving adherence, particularly to nebulisers, is a key
challenge for the prevention of progression of disease.
Successful psychosocial intervention is determined by: (i) the
Team ethos to patient care, (ii) collaboration with patients to
increase their motivation and (iii) identifying barriers and
actively supporting patients' efforts to increase treatment.
i. Teams must endorse a collaborative, nurturing and holistic
approach to adherence, based on effective information-
giving and empathic communication. Open discussion
leads to facilitating care that is individually meaningful and
accounts for needs for involvement and making informed
choice. Psycho-social professionals need to support
team-members' efforts to engage patients in conversation
using active-listening skills
ii. Persuading patients with chronic sub-optimal adherence
does not work. Psychosocial professionals must lead on
efforts to address perceptual or emotional barriers to
adherence in patients unwilling to acknowledge problems
or who lack motivation [111]
iii. A range of psychological strategies are effective (e.g.,
reinforcement scheduling, problem-solving). Clinical
trials of interventions are ongoing. Psychosocial profes-
sionals must achieve competence and provide leadership
about techniques.
7.5. What are the main components to supporting patients
diagnosed in adolescence/adulthood?
CF diagnosed beyond childhood may be for a range of reasons,
mild or mis-diagnosed symptoms or less severe phenotype [112].
Patients often are angry and overwhelmed by information
(prognosis, infertility) and ‘technical’ aspects of busy CF clinics.
This leads to challenges in building a trusting alliance. A flexible
and individualised approach to clinical management is needed for
the particular patient which differs from the routine care provided
to those diagnosed in early childhood. Emphasis must be placed
on prognosis, fertility issues, personal support, and reviewing
what CF knowledge patients may have acquired and from where
(some sources being misleading) [113].
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7.6. Disordered eating and body image problems in patients
impact on treatment and prognosis. What are the key
components in addressing these?
Competing demands from CF management including mon-
itoring of nutritional status emphasising weight gain within a
culture emphasising thinness contribute to confused attitudes
towards eating. Disordered eating and body image problems
have been reported in people with CF [114].
The approach to nutritional management needs to take account
of the patient's attitudes towards eating, shape and personal
appearance, rather than focus simply on calorie intake and weight
gain. Assessment of nutritional intake should include questions
on the above and diet plans incorporating healthy eating idea.
Educational programmes should be available to inform people
with CF about digestion, calorie consumption and energy usage
in CF. Health professionals working with people with CF should
be equipped to identify disturbed eating behaviours allowing
early detection and joint intervention between dietitian and
psychologist is recommended.
7.7. How should we tackle the key psychosocial issues of
adulthood and growing older with CF?
Key issues of adulthood are (i) normal tasks of adulthood being
made more complex due to CF, (ii) making complex decisions
(e.g. making vocational plans or making treatment decisions) and,
(iii) coping with deterioration in health and loss of mobility and
independence, as well as new complications diagnoses (e.g.,
CFRD), that can lead to, for example, increased anxiety and
depression (demoralisation), low self-esteem and relationship
difficulties.
Key approaches are:
i. A pro-active approach during routine clinics and assessment
during annual review can help identify emotional, practical
and social support requirements (e.g., employment, fertility,
risk-taking behaviours). Patients tend not to initiate these
[115,116]
ii. Referral to a CF team's psychosocial professional or
external specialist mental health services.
CF teams must be aware of the likelihood of demoralisation
occurring as a consequence of multiple health problems. This
resembles, but is different from, depression in personal impact
and treatment [117].
7.8. What are the core aspects of training and supporting the
MDT in developing psychosocial skills?
All members of the Team need to have some psychosocial
skills. A 4-step skills model is described;
i. Team members should have training to enable recognition
of psychological needs and provide information and general
psychological support. Be able to access psychiatric
services in an emergency.
ii. A team member can have additional training to: enable
screening and referral for psychological distress, administer
psychological first-aid following traumatic medical events
(e.g., haemoptysis) and implement particular psychological
techniques (e.g., desensitisation to painful procedures).
iii. Trained and accredited team member to assess for
psychological distress and implement specific therapeutic
techniques (e.g. counselling or therapy delivered accord-
ing to an explicit framework). Requires supervision from
a qualified mental health trained professional.
iv. Qualifiedmental health specialist (e.g. clinical psychologist),
who can diagnose psychopathology and treat using specialist
psychological interventions.
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